In its August 2026 issue, the Lancet-family journal eBioMedicine published a global retrospective cohort study finding that men who start testosterone therapy without evidence of hypogonadism face a 51% higher risk of major adverse cardiovascular events and nearly double the risk of death from any cause compared with matched men prescribed the same drug for documented deficiency. Harvard Health flagged the findings for a consumer audience on August 24, tying them directly to the FDA's proposed label changes that stand to widen access to the hormone.

Why It Matters

This lands squarely on the business model of direct-to-consumer men's health. Telehealth TRT platforms — and the wave of longevity and "optimization" clinics that followed them — are built on low-friction online intake, home lab kits, and a prescribing threshold considerably looser than an endocrinologist's. The study's finding that 35.4% of initiators globally had no documented hypogonadism is an implicit measurement of how much of the category sits outside the label, and a 1.51 hazard ratio attached to that segment is the kind of number that reshapes malpractice exposure, payer policy, and eventually FDA labeling. For platforms like Hims, Ro, and LifeMD, the immediate risk is not enforcement but underwriting: if cardiovascular surveillance becomes standard of care for off-label initiation, the cost structure of a $99-a-month subscription changes. For patients, the practical takeaway is unglamorous and specific — get the blood test, twice, before the prescription.

The scale is what gives the result weight. Researchers pulled de-identified structured electronic health records from 123 healthcare organizations worldwide to identify men aged 30 to 75 initiating testosterone therapy, applying a prespecified three-year pre-index washout that excluded prior testosterone use and prior major cardiovascular or thromboembolic events. Among 358,957 testosterone initiators, 127,152 — 35.4%, better than one in three — had no evidence of hypogonadism in their records. After 1:1 propensity-score matching, 113,554 pairs were followed for up to ten years.

The headline numbers: MACE occurred in 16.53% of the no-hypogonadism group versus 11.83% of the documented-deficiency group, a hazard ratio of 1.51 (95% CI 1.45–1.56). All-cause mortality carried a hazard ratio of 1.90 (1.79–2.00). Secondary outcomes moved in the same direction — ischaemic stroke HR 1.23, cardiac arrest HR 1.41, heart failure HR 1.32. Acute appendicitis served as a negative-control outcome, a standard design check against unmeasured confounding. Race-stratified estimates were directionally consistent but varied in magnitude, which the authors flag as clinically relevant heterogeneity.

The caveats are real and the authors state them: this is observational, and the two groups differ in ways records cannot fully capture. Harvard's write-up is explicit that the findings "don't prove that testosterone, even in men without hypogonadism, is responsible for the elevated heart risks." The authors' recommendation is a full clinical evaluation before initiation and cardiovascular risk surveillance during treatment — "biologically informed prescribing," in the paper's phrasing.

Context matters for the timing. In February 2025 the FDA removed the boxed cardiovascular warning from all testosterone products following the TRAVERSE trial, which found no increased MACE risk among hypogonadal men with elevated cardiovascular risk. Epic Research data published in July 2026 showed US testosterone prescribing subsequently rebounded past its early-2010s peak to an all-time high of 0.95% of adult male patients. The distinction the new study draws is precisely the one TRAVERSE did not test: TRAVERSE studied men with hypogonadism. This cohort studied the third of prescriptions that go to men without it.

Sources

Update — 2026-08-27

{Initial entry — story first created.}